TriangleNCT01363479 · CITED IN SOURCE DOCUMENTS
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.
- Phase
- PHASE3
- Status at capture
- COMPLETED
- Registry last update
- 2021-09-22
PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that oral palonosetron 0.50 mg is as effective as (non-inferior to) palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Naïve to cytotoxic chemotherapy. Previous biological or hormonal therapy is permitted. * Diagnosed with a malignant solid tumor and scheduled to receive first course of cytotoxic chemotherapy with cisplatin administered as a single I.V. dose of equal or more than 70 mg/m2 over 1-4 hours on study Day 1, either alone or in combination with other chemotherapeutic agents. * If scheduled to receive combination regimens, non-cisplatin agents of moderate to high emetogenic potential are allowed and they must be administered following the cisplatin infusion and completed no more than 6 hours after the initiation of cisplatin infusion. * If scheduled to receive chemotherapy agents of minimal to low emetogenic potential, they are to be given on Day 1 following cisplatin or on any subsequent study day. * ECOG Performance Status of 0, 1, or 2 * Female patients of either non-childbearing potential or child-bearing potential with a commitment to use contraceptive methods throughout the clinical trial * Hematologic and metabolic status adequate for receiving a highly emetogenic cisplatin-based regimen based on laboratory criteria (Neutrophils,Platelets, Bilirubin, Liver enzymes, Serum Creatinine or Creatinine Clearance) * If a patient has a known hepatic or renal impairment, he/she may be enrolled in this study at the discretion of the Investigator. * If a patient has a known history or predisposition to cardiac conduction interval abnormalities he/she may be enrolled in this study at the discretion of the Investigator. Exclusion Criteria: * If female, pregnant or lactating. * Current use of illicit drugs or current evidence of alcohol abuse. * Scheduled to receive moderately emetogenic chemotherapy (MEC) or HEC from Day 2 to Day 5 following cisplatin administration. * Received or is scheduled to receive radiation therapy to the abdomen, or the pelvis within 1 week prior to Day 1 or between Days 1 to 5. * Any vomiting, retching, or mild nausea within 24 hours prior to Day 1. * Symptomatic primary or metastatic CNS malignancy. * Active peptic ulcer disease, gastrointestinal obstruction, increased intracranial pressure, hypercalcemia, an active infection or any uncontrolled medical conditions (other than malignancy) that, in the opinion of the investigator, may confound the results of the study, represent another potential etiology for emesis and nausea (other than chemotherapy-induced nausea and vomiting, CINV) or pose unwarranted risks in administering the study drugs to the patient. * Known hypersensitivity or contraindication to 5-HT3 receptor antagonists (e.g., palonosetron, ondansetron, granisetron, dolasetron, tropisetron, ramosetron) or dexamethasone. * Participation in a clinical trial involving palonosetron. * Any investigational drugs (other than those given in this study) taken within 4 weeks prior to Day 1, and/or is scheduled to receive any investigational drug during the study. * Systemic corticosteroid therapy at any dose within 72 hours prior to Day 1. However topical and inhaled corticosteroids with a steroid dose of £ 10 mg of prednisone daily or its equivalent are permitted. * Scheduled to receive bone marrow transplantation and/or stem cell rescue therapy. * Any medication with known or potential antiemetic activity within 24 hours prior to Day 1
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- Oral palonosetron (Aloxi 0.50 mg softgel capsule) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
- intervention Names
- Drug: Oral palonosetron
- Drug: Dexamethasone
- label
- Oral palonosteron plus dexamethasone
- type
- EXPERIMENTAL
- description
- Intravenous palonosetron (Aloxi 0.25 mg solution for injection) with oral dexamethasone, both given on Day 1, prior to the scheduled start of cisplatin; then dexamethasone from Days 2 through 4.
- intervention Names
- Drug: I.V. palonosetron
- Drug: Dexamethasone
- label
- I.V. palonosetron plus dexamethasone
- type
- ACTIVE_COMPARATOR
- interventions
- arm Group Labels
- Oral palonosteron plus dexamethasone
- name
- Oral palonosetron
- type
- DRUG
- arm Group Labels
- I.V. palonosetron plus dexamethasone
- name
- I.V. palonosetron
- type
- DRUG
- arm Group Labels
- I.V. palonosetron plus dexamethasone
- Oral palonosteron plus dexamethasone
- name
- Dexamethasone
- type
- DRUG
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- QUADRUPLE
- who Masked
- PARTICIPANT
- CARE_PROVIDER
- INVESTIGATOR
- OUTCOMES_ASSESSOR
- primary Purpose
- PREVENTION
Enrollment
- count
- 743
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- measure
- Percentage of Patients With Complete Response (CR) Defined as no Emesis, no Rescue Medication
- time Frame
- 0-24 hours
- secondary Outcomes
- measure
- Percentage of Patients With no Emesis
- time Frame
- 0-24 hours
- measure
- Percentage of Patients With no Rescue Medication
- time Frame
- 0-24 hours
Full study description
- brief Summary
- PALO-10-01 is a clinical study assessing efficacy and safety of a single oral dose of palonosetron compared to a single intravenous dose of palonosetron (Aloxi, an antiemetic drug), both given with oral dexamethasone. The objective of the study is to demonstrate that oral palonosetron 0.50 mg is as effective as (non-inferior to) palonosetron IV 0.25 mg to prevent nausea and vomiting induced by highly emetogenic cancer chemotherapy in the 0-24 hours after administration of a single cycle of highly emetogenic chemotherapy.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-7ad944f6deaf1f5cd6122126
- edge id
- nct-edge-d9a54caa9aced05ed332
- requested nct id
- NCT01363479
- primary nct id
- NCT01363479
- source kind
- fda_spl_label
- source record id
- c1a46993-d1bf-4f84-8fac-e9c04a7d6bf1
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- payload sha256
- c39cf35dc7c515d173532fa0c4d7498182dad0ccb07fe88ae774580e80a73d6d
- payload
- application numbers
- NDA205718
- NDA210493
- clinical indication matching status
- not_inferred
- end exclusive
- true
- id
- nct-edge-d9a54caa9aced05ed332
- link basis
- explicit_NCT_identifier_in_acquired_source
- nct id
- NCT01363479
- occurrences
- context exact
- emotherapy (including carboplatin, cisplatin, oxaliplatin, and doxorubicin regimens) received AKYNZEO; efficacy was maintained throughout all cycles. Study 4 ( NCT01363479 ) In a multicenter, multinational, randomized, active‑controlled, double‑blind, double‑dummy, parallel group, clinical non-inferiority study, the efficacy and
- end
- 6396
- exact text
- NCT01363479
- start
- 6385
- offset unit
- unicode_code_points
- source file
- /tmp/cancer-full-research/indications/raw/labels-00600.json
- source file sha256
- a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6
- source json pointer
- /results/48/clinical_studies/0
- source kind
- fda_spl_label
- source record id
- c1a46993-d1bf-4f84-8fac-e9c04a7d6bf1
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 40fb980a67afbc7b246cf52fd3b76f1ee849d8f5e1441e858a9615c872996105
- spl effective time
- 20260623
- spl set id
- 8e47618e-af46-4d82-94e8-1507c042252d
Preserved source evidence · Not medical advice